Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18041972 | 0.91 | MAPK14 (0.92) | MAPK14CYP3A4 | |
| SCHEMBL5795245 | 0.89 | MAPK14 (1.00) | MAPK14CYP3A4 | |
| SCHEMBL18041755 | 0.89 | MAPK14 (0.92) | MAPK14CYP3A4 | |
| SCHEMBL18041529 | 0.88 | MAPK14 (0.77) | MAPK14CYP3A4 | |
| SCHEMBL5769870 | 0.87 | MAPK14 (1.00) | MAPK14CYP3A4 | |
| SCHEMBL18041883 | 0.86 | MAPK14 (0.81) | MAPK14CYP3A4 | |
| SCHEMBL18041769 | 0.85 | MAPK14 (0.74) | MAPK14CYP3A4 | |
| SCHEMBL5773742 | 0.85 | MAPK14 (0.78) | MAPK14CYP3A4 | |
| SCHEMBL18041849 | 0.82 | MAPK14 (0.78) | MAPK14CYP3A4 | |
| SCHEMBL5770118 | 0.79 | MAPK14 (0.76) | MAPK14CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352360-B2 | TGF-beta inhibitors | Rigel Pharmaceuticals, hic. (US) | 2022-06-07 | — | — | US | disclosed |
| CN-107406412-B | TGF-beta inhibitors | 里格尔药品股份有限公司 | 2021-07-16 | — | — | CN | disclosed |
| US-20200031832-A1 | TGF-Beta Inhibitors | MIDCAP FINANCIAL TRUST | 2020-01-30 | — | — | US | disclosed |
| US-10287295-B2 | TGF-β inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2019-05-14 | — | — | US | disclosed |
| US-20180127426-A1 | TGF-Beta Inhibitors | MIDCAP FINANCIAL TRUST | 2018-05-10 | — | — | US | disclosed |
| US-9884868-B2 | TGF-beta inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2018-02-06 | — | — | US | disclosed |
| US-20160257690-A1 | TGF-Beta Inhibitors | MIDCAP FINANCIAL TRUST | 2016-09-08 | — | — | US | disclosed |
| US-7320995-B2 | Benzimidazoles and benzothiazoles as inhibitors of map kinase | ELI LILLY AND COMPANY (US) | 2008-01-22 | — | — | US | disclosed |
| EP-1554272-B1 | BENZIMIDAZOLES AND BENZOTHIAZOLES AS INHIBITORS OF MAP KINASE | LILLY CO ELI (US) | 2006-10-25 | — | — | EP | disclosed |
| US-20050272791-A1 | Benzimidazoles and benzothiazoles as inhibitors of map kinase | EIL LILLY AND COMPANY (US) | 2005-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352360-B2 | TGF-beta inhibitors | TGFBR1, TGFBR2, TGFB1 | MAPK14 2266/4885CYP3A4 3457/4885 |
| US-20050272791-A1 | Benzimidazoles and benzothiazoles as inhibitors of map kinase | MAP3K8, MAPK8, MAPK1 | MAPK14 10/4885CYP3A4 2862/4885 |
| US-20200031832-A1 | TGF-Beta Inhibitors | TGFBR1, TGFBR2, TGFB1 | MAPK14 2266/4885CYP3A4 3457/4885 |
| US-20180127426-A1 | TGF-Beta Inhibitors | TGFBR1, TGFBR2, TGFB1 | MAPK14 2266/4885CYP3A4 3457/4885 |
| US-10287295-B2 | TGF-β inhibitors | TGFBR1, TGFBR2, TGFB1 | MAPK14 2085/4885CYP3A4 3442/4885 |
| US-20160257690-A1 | TGF-Beta Inhibitors | TGFBR1, TGFBR2, TGFB1 | MAPK14 2266/4885CYP3A4 3457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.